Repare Therapeutics Inc. (RPTX)
NASDAQ: RPTX · Real-Time Price · USD
1.140
-0.045 (-3.80%)
At close: Mar 10, 2025, 4:00 PM
1.200
+0.060 (5.26%)
Pre-market: Mar 11, 2025, 7:17 AM EST
Repare Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 53.48 | 51.13 | 131.83 | 7.6 | 0.14 | |
| Revenue Growth (YoY) | 4.58% | -61.21% | 1634.61% | 5529.63% | - | |
| Cost of Revenue | - | 131.2 | 116.72 | 87.85 | 38.78 | |
| Gross Profit | 53.48 | -80.07 | 15.11 | -80.25 | -38.64 | |
| Selling, General & Admin | 29.68 | 36.15 | 34.9 | 28.41 | 15.66 | |
| Research & Development | 115.94 | - | - | - | - | |
| Operating Expenses | 145.62 | 36.15 | 34.9 | 28.41 | 15.66 | |
| Operating Income | -92.14 | -116.22 | -19.8 | -108.66 | -54.3 | |
| Interest & Investment Income | 10.39 | 13.33 | 5.63 | 0.26 | 0.24 | |
| Currency Exchange Gain (Loss) | -0 | -0.17 | 0.31 | -0.14 | -0.66 | |
| Other Non Operating Income (Expenses) | -0.12 | -0.12 | -0.04 | -0.04 | -0.02 | |
| EBT Excluding Unusual Items | -81.87 | -103.18 | -13.9 | -108.59 | -54.74 | |
| Merger & Restructuring Charges | -1.38 | - | - | - | - | |
| Pretax Income | -83.25 | -103.18 | -13.9 | -108.59 | -54.74 | |
| Income Tax Expense | 1.44 | -9.38 | 15.15 | -1.68 | -1.33 | |
| Net Income | -84.69 | -93.8 | -29.05 | -106.91 | -53.42 | |
| Net Income to Common | -84.69 | -93.8 | -29.05 | -106.91 | -53.42 | |
| Shares Outstanding (Basic) | 42 | 42 | 42 | 38 | 20 | |
| Shares Outstanding (Diluted) | 42 | 42 | 42 | 38 | 20 | |
| Shares Change (YoY) | 0.75% | 0.41% | 10.85% | 88.66% | 1211.56% | |
| EPS (Basic) | -2.00 | -2.23 | -0.69 | -2.83 | -2.66 | |
| EPS (Diluted) | -2.00 | -2.23 | -0.69 | -2.83 | -2.66 | |
| Free Cash Flow | -76.45 | -129.1 | -0.28 | -87.49 | -8.32 | |
| Free Cash Flow Per Share | -1.80 | -3.07 | -0.01 | -2.31 | -0.42 | |
| Gross Margin | 100.00% | -156.59% | 11.46% | - | - | |
| Operating Margin | -172.31% | -227.30% | -15.02% | -1429.74% | -40223.70% | |
| Profit Margin | -158.37% | -183.44% | -22.03% | -1406.68% | -39568.15% | |
| Free Cash Flow Margin | -142.95% | -252.47% | -0.21% | -1151.13% | -6163.70% | |
| EBITDA | -90.22 | -114.27 | -17.82 | -107.19 | -53.41 | |
| EBITDA Margin | -168.71% | -223.48% | -13.52% | - | - | |
| D&A For EBITDA | 1.92 | 1.95 | 1.98 | 1.47 | 0.9 | |
| EBIT | -92.14 | -116.22 | -19.8 | -108.66 | -54.3 | |
| EBIT Margin | -172.31% | -227.30% | -15.02% | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.